ArticleOncotarget2017
Association of high microvessel α
Open access · diamondAbstract read
In one paragraph
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review.Cancer metastasis reviews · 2024Review
- Epigenetic Dysregulation inInternational journal of molecular sciences · 2023Review
- Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.Pharmaceutics · 2023Review
- Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.International journal of molecular sciences · 2021Review
- Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.Molecules (Basel, Switzerland) · 2021Review
- CD146 is a potential immunotarget for neuroblastoma.Cancer science · 2021Article
- MYCN in Neuroblastoma: "Old Wine into New Wineskins".Diseases (Basel, Switzerland) · 2021Review
- Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.Journal of pediatric surgery · 2021Article
- BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma.Cancers · 2021Article
- Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.International journal of medical sciences · 2021Article
- The Tumor Microenvironment in Neuroblastoma: New Players, New Mechanisms of Interaction and New Perspectives.Cancers · 2020Review
- Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions.Cancers · 2020Review
- Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.EMBO molecular medicine · 2019Article
- Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System.Journal of oncology · 2019Review
- Neuroblastoma: clinical and biological approach to risk stratification and treatment.Cell and tissue research · 2018Review
- Aberrant expression of ALDH1, MMP9, Integrin αvβ3, and KiSS-1 in invasive ductal carcinoma and their clinical significance.International journal of clinical and experimental pathology · 2018Article
- A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers.The Yale journal of biology and medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 2 countries.
Anat Erdreich-Epstein *Department of Pediatrics, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Alok R SinghDepartment of Pediatrics, Moores Cancer Center, University of California San Diego, California, USA.
Shweta JoshiDepartment of Pediatrics, Moores Cancer Center, University of California San Diego, California, USA.
Francisco M VegaDepartment of Pediatrics, Moores Cancer Center, University of California San Diego, California, USA.
Pinzheng GuoDepartment of Pediatrics, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Jingying XuDepartment of Pediatrics, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Susan GroshenDepartment of Preventive Medicine, Keck School of Medicine, Los Angeles, California, USA.
Wei YeDepartment of Preventive Medicine, Keck School of Medicine, Los Angeles, California, USA.
Melissa MillardDepartment of Pediatrics, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Mihaela CampanDepartment of Surgery University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Guillermo MoralesSignalRx Pharmaceuticals, San Diego, California, USA.
Joseph R GarlichSignalRx Pharmaceuticals, San Diego, California, USA.
Peter W LairdDepartment of Surgery University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Robert C SeegerDepartment of Pediatrics, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Hiroyuki ShimadaDepartment of Pathology, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Donald L Durden *Department of Pediatrics, Moores Cancer Center, University of California San Diego, California, USA.
Children's Hospital of Los Angeles · USUniversity of Southern California · USSignalRx Pharmaceuticals (United States) · USUniversity of California, San Diego · USInstituto de Biomedicina de Sevilla · ESRady Children's Hospital-San Diego · USVan Andel Institute · US
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4MVascular endothelial cell integrins in angiogenesisP01CA081403 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI SEEGER, ROBERT CHARLES · 2000 to 2014
$28.5MCLINICAL CORRELATIVE STUDIES OF NEUROBLASTOMAR01CA060104 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI SEEGER, ROBERT CHARLES · 1998 to 2010
$5.3MVascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapyR01CA094233 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DURDEN, DONALD · 2002 to 2012
$2.4MDevelopment of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523R42CA192656 · NCI · SIGNALRX PHARMACEUTICALS, INC. · PI MORALES, GUILLERMO A · 2017 to 2018
$2.0MPhase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade GliomasR01FD004385 · FDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DURDEN, DONALD · 2014 to 2017
$1.6MBrain tumor angiogenesis: Integrin ceramide signalingR01CA098568 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI ERDREICH-EPSTEIN, ANAT · 2004 to 2008
$1.4MVascular targeted pan PI-3kinase inhibitor prodrug, SF1126 for glioma therapy.R56CA094233 · NCI · EMORY UNIVERSITY · PI DURDEN, DONALD · 2008 to 2008
$224kMaximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitorsR41CA192656 · NCI · SIGNALRX PHARMACEUTICALS, INC. · PI DURDEN, DONALD · 2015 to 2015
$209kFDA HHS R01 FD004385NCI NIH HHS P01 CA081403NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA060104NCI NIH HHS R01 CA094233NCI NIH HHS R01 CA098568NCI NIH HHS R41 CA192656NCI NIH HHS R42 CA192656NCI NIH HHS R56 CA094233
Abstract
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Our previous studies showed that the angiogenic integrin α
Indexed as
angiogenesisBRD4integrin αvβ3neuroblastomaPI3-kinase inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.